Previous 10 | Next 10 |
2024-03-13 14:40:02 ET Liquidia Corporation (LQDA) Q4 2023 Earnings Conference Call March 13, 2024, 8:30 a.m. ET Company Participants Roger Jeffs - CEO Scott Moomaw - CCO Michael Kaseta - COO & CFO Rajeev Saggar - CMO Jason Adair - CBO Rusty Schun...
SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...
2024-03-13 06:03:14 ET More on Liquidia Liquidia Corporation: A Complicated Tale Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas Liquidia says FDA review for...
Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approval Federal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent invalid Advancing industry leading portfolio for inhaled treprostinil with YUT...
2024-03-12 11:22:10 ET More on Liquidia Liquidia Corporation: A Complicated Tale Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas Liquidia says FDA review for...
MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a cor...
2024-03-03 10:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-15 11:35:43 ET Summary Liquidia Corporation shares rallied over 80% after an appeals court invalidated the patent of rival United Therapeutics, potentially paving the way for approval of its PAH and PH-ILD medication Yutrepia. However, the FDA recently extended the origina...
2024-02-14 19:49:34 ET Summary MannKind sold a 10% stake in Tyvaso DPI for $150 million upfront, with an additional $50 million possible, indicating the potential value of the remaining 9% to be upwards of $1.8 billion. Liquidia's likely entry into the market with a competing form...
2024-02-12 22:49:38 ET Summary Liquidia's stock has increased in value by 209.32% since June 2022. Liquidia's PAH drug, Yutrepia, is expected to launch in the first or second quarter of 2024, potentially leading to profitability. Liquidia has gained a major partnership for a s...
News, Short Squeeze, Breakout and More Instantly...
Liquidia Technologies Inc. Company Name:
LQDA Stock Symbol:
NASDAQ Market:
Liquidia Technologies Inc. Website:
MORRISVILLE, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024. The company will host a webcast at 8:30 a.m. ET on May 14, 2024 to discuss the financial results and provide a c...
2024-05-12 11:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MORRISVILLE, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today the company will present data related to...